Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-11 of 11 for your search:
Cancer Type:
Kidney (renal cell) cancer
Trial Type:
Treatment
Treatment/Intervention:
antiangiogenesis therapy
Trial Status:
Active
Trial Phase:
Phase III
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
A6181037
, NCT00130897
2.
Phase III Randomized Study of Adjuvant Sunitinib Malate Versus Sorafenib in Patients With Resected Renal Cell Carcinoma
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ECOG-E2805
, E2805, CALGB-E2805, SWOG-E2805, CAN-NCIC-E2805, NCT00326898
3.
Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
VEG107769
, NCT00387764
4.
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
A6181114
, NCT00428220
5.
Phase III Randomized Study of Sorafenib Tosylate in Patients With Resected Primary Renal Cell Carcinoma at High- or Intermediate-Risk of Relapse
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
Other
Protocol IDs:
MRC-RE05-SORCE
, MRC-RE05-SORCE, EUDRACT ID 2006-006079-19, EU-20734, NCT00492258, SORCE, ISRCTN38934710
6.
Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
12750
, NCT00478114
7.
Study Comparing Bevacizumab + Temsirolimus Vs Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
3066K1-3311
, NCT00631371
8.
Axitinib (Ag 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
A4061032
, AXIS TRIAL, NCT00678392
9.
Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
108844
, COMPARZ, NCT00720941
10.
Sequential Study to Treat Renal Cell Carcinoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
Other
Protocol IDs:
09072008-13772
, EudraCT 2008-005011-18, NCT00732914
11.
Phase III Randomized Study of Pazopanib Hydrochloride in Patients With Refractory or Relapsed Metastatic Soft Tissue Sarcoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
EORTC-62072
, EORTC 62072, EU-20887, NCT00753688, PALETTE, GSK-VEG110727, EUDRACT-2008-001307-33
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
